About Verifone This stock analysis article is a bit different from what we’ve traditionally done in the past, although we’ve put together our fair share of theoretical acquisition analysis articles as well as hedge fund manager analysis articles. So it’s not completely out of left field. Contrary to one’s initial belief, Verifone is not some […]
Should Verifone Acquire Square? Read More »
About Regeneron Pharmaceuticals For whatever reason, pharmaceutical companies and their stocks have been the word on the street at MacroHint. Regeneron is by no means an exception. Aside from having a name that sounds like one of the lost members of the Transformer’s, at its core Regeneron is a serious disease company, essentially focused on
Stock Analysis: Regeneron Pharmaceuticals (NASDAQ: REGN) Read More »
About Verisign It is safe to say that if the internet goes down for more than two seconds, people will absolutely lose their minds. This goes to show that what Verisign does is akin to the core concept of insurance; you don’t miss it or think about it when things are going well but when
Stock Analysis: Verisign (NASDAQ: VRSN) Read More »
About Cedar Fair If you don’t like the carnival, that’s fair. Do you like what we did there? Well, if you didn’t it’s a good thing that Cedar Fair isn’t 100% what it sounds like. Although the company’s stock ticker symbol is an accurate portrayal of what you will likely be having while at one
Stock Analysis: Cedar Fair (NYSE: FUN) Read More »
About Churchill Downs We at MacroHint like to think, analyze, think some more, write and then edit. And then think again. We also don’t consider ourselves to be particularly attracted to or attached to material things. The same might not necessarily be true for those who like to fly down on their private planes, hop
Stock Analysis: Churchill Downs (NASDAQ: CHDN) Read More »
About Alnylam Pharmaceuticals Alnylam is your run of the mill biopharmaceutical company. It has certain products it specializes in that separate itself from the competition, as is the case from other pharmaceutical companies, small and large. According to TD Ameritrade’s platform, Alnylam primarily focuses on and is “developing therapeutics based on ribonucleic acid interference (RNAi),”
Stock Analysis: Alnylam Pharmaceuticals (NASDAQ: ALNY) Read More »
About Build-A-Bear Workshop TD Ameritrade’s platform categorizes Build-A-Bear Workshop’s industry as “Consumer Discretionary: Specialty Retail.” They pretty much nailed it on the head with that one. While we’re not crazy about the retail sector, especially as consumers continue to trade and pare down on their spending, although some of the larger retail establishments have a
Stock Analysis: Build-A-Bear Workshop (NYSE: BBW) Read More »
About CrowdStrike You know how a lot of people claim to be visionaries and that they have an innate ability to accurately predict the state of the world in the next few years? We don’t claim to have that ability. There is no (legal) crystal ball and there is no such thing as perfectly predicting
Stock Analysis: CrowdStrike (NASDAQ: CRWD) Read More »
About Joe Tsai Many across the globe have traveled to America and subsequently found themselves living and embodying the American dream. As we’ve outlined and highlighted in previous stock analysis articles, the United States has made it possible for many to prosper in more ways than none, especially financially. However, hard work, dedication, vision and
Joe Tsai’s Stock Portfolio Read More »
About Philip Morris International There is a lot to be said about the tobacco industry. Since the inception of tobacco and its many applications, then morphing into the everyday cigarette and now vape, tobacco is an industry that is likely to never go away due to its addictive nature (mainly through usage of nicotine) and
Stock Analysis: Philip Morris International (NYSE: PM) Read More »